Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

SPINEWAY : Ordinary and Extraordinary General Shareholders' Meeting of 13 September Access to preparatory documentation


Posted on: 08 Aug 18

Press release                                                                                                                                                                       Ecully, 8 August 2018

Ordinary and Extraordinary General Shareholders' Meeting of 13 September
Access to preparatory documentation

The shareholders of SPINEWAY are invited to attend the Ordinary and Extraordinary General Shareholders' Meeting to be held on Thursday, 13 September 2018, at 2:00 p.m., at SPINEWAY's registered office, located at 7 allée du Moulin Berger, 69130 Ecully.

Notice of the meeting, serving as convocation, setting forth the agenda and draft resolutions was published in France's legal gazette (BALO) on 8 August 2018.

Any shareholder can submit a written request, in accordance with the terms and deadlines set forth in article R.225-88 of the French Commercial Code, to Spineway, 7 allée du Moulin Berger, 69130 Ecully, asking the company to send the documents and information referred to in articles R. 225-81 and R. 225-83 of the French Commercial Code to the postal address given by said shareholder.

Any shareholder can, in accordance with the terms and deadlines set forth in articles R. 225-89 and R. 225- 90 of the French Commercial Code, consult such documents and information mentioned in said articles at Spineway's registered office.

The information and documents in connection with this meeting can be found on the Company's website, as follows: http://www.spineway.com/finance/?content=index7&display=FR

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com

Next communication: Half-year results for 2018 - 24 October 2018

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation Award (2013) - INPI Talent award (2015). ISIN: FR0011398874 - ALSPW

Contacts:

Investor relations
David Siegrist - Directeur Financier
Phone: +33 (0)4 72 77 01 52
finance.dsg@spineway.com
  Financial communication
Jérôme Gacoin / Solène Kennis
Phone: +33 (0)1 75 77 54 68
skennis@aelium.fr

Attachment

GlobeNewswire
globenewswire.com

Last updated on: 08/08/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.